Recombinant Human CD38 Protein (C-His)

Measured by functional ELISA. Immobilized recombinant human CD38 binds reference anti-CD38 antibodies daratumumab and isatuximab with EC50 values in the range of 10–50 ng/mL.

CD38 is a type II transmembrane ectoenzyme whose extracellular domain catalyzes the synthesis and hydrolysis of cyclic ADP-ribose, linking surface receptor signaling to intracellular calcium mobilization and NAD+ metabolism. As a marker, CD38 is expressed at high density on plasma cells, activated T and NK cells and myeloid cells, and its uniform, intense expression on multiple myeloma cells made it an outstanding therapeutic target: the CD38 antibodies daratumumab and isatuximab achieve deep responses in myeloma through Fc-mediated effector mechanisms and immune modulation. CD38 is also a rising target in autoimmune disease and sickle-cell research. The soluble extracellular domain presented here supports anti-CD38 antibody screening, biosimilar potency testing, enzyme-activity studies and diagnostic assay development.